This is a working overview of research peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-26. Anything still debated is marked as such rather than presented as settled.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
The musculoskeletal system the organ system that gives humans the ability to move using their muscular and skeletal systems, and is described by the anatomical terms of bone and muscle. It is made up of the bones of the skeleton, muscles, cartilage, tendons, ligaments, joints, and other connective tissue that supports and binds tissues and organs together:
== Structure and functions of procollagen galactosyltransferase 1 == Procollagen galactosyltransferase 1 (GT251), encoded by the COLGALT1 gene, plays a crucial role in lysyl O-linked glycosylation and the maturation of collagen. GT251 consists of two galactosyltransferase domains (GalT-N and GalT-C) and is stabilized in a dimeric form. The GT251 dimer can further associate with LH3 (encoded by PLOD3) to form a heterotetrameric complex, known as the KOGG complex (Lysyl Hydroxylation-Galactosylation-Glucosylation complex). Within this complex, three key enzymatic reactions in lysine O-linked glycosylation are coordinately catalyzed by LH3 and GT251, ensuring proper collagen modification and structural integrity.
This enzyme is an oxidoreductase, oxidizing the CH-OH alcohol group to a carbonyl group. NAD+ is the oxidizing agent, yielding reduced NADH. Aryllactates and arylpyruvates are intermediates in tyrosine, phenylalanine and tryptophan metabolism and blood serum levels of these compounds affect intestinal permeability and systemic immunity in mice. Alternative names for these enzymes are: (R)-aromatic lactate dehydrogenase, D-aryllactate D-hydrogenase, (indol-3-yl)lactate:NAD+ oxidoreductase, indolelactate:NAD+ oxidoreductase, (R)-4-hydroxyphenyllactate dehydrogenase, (R)-3-(4-hydroxyphenyl)lactate:NAD(P)+ 2-oxidoreductase
Sources: en.wikipedia.org
=== History === Fu, Jia-Chen; King, Michelle; Klein, Jakob, eds. (2025). Modern Chinese Foodways. MIT Press. ISBN 9780262381642. Chang, Kwang-chih (1977). Food in Chinese Culture: Anthropological and Historical Perspectives. New Haven: Yale University Press. ISBN 0300019386. David R. Knechtges, "A Literary Feast: Food in Early Chinese Literature," Journal of the American Oriental Society 106.1 (1986): 49–63. Newman, Jacqueline M. (2004). Food Culture in China. Westport, Conn.: Greenwood Press. ISBN 0313325812. Roberts, J. A. G. (2002). China to Chinatown: Chinese Food in the West. London: Reaktion. ISBN 1861891334. Sterckx, Roel. Food, Sacrifice, and Sagehood in Early China. New York: Cambridge University Press, 2011 (2015). Sterckx, Roel. Chinese Thought. From Confucius to Cook Ding. London: Penguin, 2019. Swislocki, Mark (2009). Culinary Nostalgia: Regional Food Culture and the Urban Experience in Shanghai. Stanford, CA: Stanford University Press. ISBN 9780804760126. Waley-Cohen, Joanna (2007). "Celebrated Cooks of China's Past". Flavor & Fortune. 14 (4): 5–7, 24. Archived from the original on 2 April 2015. Endymion Wilkinson, "Chinese Culinary History (Feature Review)," China Review International 8.2 (Fall 2001): 285–302. Wilkinson, Endymion (2022). Chinese History: A New Manual. Cambridge, MA: Harvard University Press. ISBN 978-0674260184. Wu, David Y. H.; Cheung, Sidney C. H. (2002). The Globalization of Chinese Food. Richmond, Surrey: Curzon. ISBN 0700714030.
Diffusion force caused by a concentration gradient - all particles tend to diffuse from higher concentration to lower. Electrostatic force caused by electrical potential gradient - cations like protons H+ tend to diffuse down the electrical potential, from the positive (P) side of the membrane to the negative (N) side. Anions diffuse spontaneously in the opposite direction. These two gradients taken together can be expressed as an electrochemical gradient. Lipid bilayers of biological membranes, however, are barriers for ions. This is why energy can be stored as a combination of these two gradients across the membrane. Only special membrane proteins like ion channels can sometimes allow ions to move across the membrane (see also: Membrane transport). In the chemiosmotic hypothesis a transmembrane ATP synthase is central to convert energy of spontaneous flow of protons through them into chemical energy of ATP bonds. Hence researchers created the term proton-motive force (PMF), derived from the electrochemical gradient mentioned earlier. It can be described as the measure of the potential energy stored (chemiosmotic potential) as a combination of proton and voltage (electrical potential) gradients across a membrane. The electrical gradient is a consequence of the charge separation across the membrane (when the protons H+ move without a counterion, such as chloride Cl−).
=== Chronic pain === Severe beak trimming or beak trimming birds at an older age is thought to cause chronic pain. Following beak trimming of older or adult hens, the nociceptors in the beak stump show abnormal patterns of neural discharge, which indicate acute pain. Neuromas, tangled masses of swollen regenerating axon sprouts, are found in the healed stumps of birds beak trimmed at 5 weeks of age or older and in severely beak trimmed birds. Neuromas have been associated with phantom pain in human amputees and have therefore been linked to chronic pain in beak trimmed birds. If beak trimming is severe because of improper procedure or done in older birds, the neuromas will persist which suggests that beak trimmed older birds experience chronic pain, although this has been debated.
== See also == Discrete Fourier transform – Function in discrete mathematics − for computing periodicity in evenly spaced data Fourier transform – Mathematical transform that expresses a function of time as a function of frequency Fourier transform spectroscopy – Spectroscopy based on time- or space-domain dataPages displaying short descriptions of redirect targets Least-squares spectral analysis – Periodicity computation method − for computing periodicity in unevenly spaced data
Sources: en.wikipedia.org
=== Angiotensin II === Angiotensin II is a key component of the renin-angiotensin system and is traditionally recognized for its role as an extracellular hormone regulating blood pressure, fluid balance, and vascular function. However, emerging evidence suggests that Ang II also functions as an intracrine factor within cardiac myocytes and vascular smooth muscle cells. This intracrine role of Ang II contributes to cardiac hypertrophy, fibrosis, and arrhythmogenesis, making it a critical regulator of cardiovascular physiology and pathology.
The Mystery of the Yellow Room at Project Gutenberg The Mystery of the Yellow Room at Standard Ebooks The Mystery of the Yellow Room public domain audiobook at LibriVox L'univers de Joseph Rouletabille, rouletabille.perso.cegetel.net (in French) The Mystery of the Yellow Room, audio version, litteratureaudio.com (in French) The Mystery of the Yellow Room at IMDb
=== Gut microbiome === In several chronic liver diseases, the gut microbiome, which regulates both the innate and adaptive immune systems, is implicated. This can result in abnormal immunological development and an accumulation of primary bile acids. Using this information a bile-acid–intestinal-microbiota–cholestasis triangle is thought to be involved in the pathogenesis of PBC and PSC. After all, bile acids do modulate the gut microbiota; a disturbance here can result in development and progression of cholestasis. This information has prompted researchers into manipulating the microbiota via antibiotics and probiotics for new treatment options. Some antibiotics examined for PSC include vancomycin, which has extensively studied and reviewed. The usage of the drug is found along with a significant decrease in ALP levels, although the long term clinical benefit is unknown. As biochemistry technology becomes more advanced, promising targets have appeared, prompting numerous studies and trials to evaluate the feasibility. Fibrates, FXR agonists, and norUDCA are all innovative therapies for cholestasis.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.